OXS-1615 is a tetraspecific ADC in preclinical development that targets EpCAM+ present on the majority of solid tumors and CD133+, an established cancer stem cell marker. Potential indications for OXS-1615 consist of carcinomas including breast, prostate, pancreatic, head and neck, colon, kidney, liver, and lung.

OXS-1615 has been licensed from the University of Minnesota.